Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mosunetuzumab→

Mosunetuzumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1905409-39-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
CD20-directed CD3 T-cell-engaging bispecific monoclonal antibodyantineoplastic biologic
Mechanism of action
Binds CD20 on B cells and CD3 on T cells, bringing T cells into proximity with malignant B cells and inducing T-cell activation and B-cell lysis.
Indications / reported uses
  • Treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy under the US product indication; EU product indications and line-of-therapy requirements should be checked separately

Sources: US DailyMed — LUNSUMIO (mosunetuzumab-axgb) · EMA EPAR — Lunsumio · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mosunetuzumab Environmental Risk Assessment (ERA) (the Mosunetuzumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.